Penny Stocks To Buy Now | 1$ Stocks

Welcome to another article in this article we talk about penny stocks to buy now. Hope you like it. Let’s get started.

Penny stocks to buy now

1.Clene Inc.

Stock Price: $0.30 (+$0.02)
PE Ratio: -0.64
Market Cap: $38.09 million
Average Trading Volume: 1.48 million shares
Consensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $7.80 (2,529.8% Upside)

Clene Inc., a clinical-stage drug organization, centers around the revelation, improvement, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being concentrated on in different clinical preliminaries, including a Stage 2/3 registrational clinical preliminary for patients with amyotrophic sidelong sclerosis (ALS); finished Stage 2 proof of idea clinical preliminary in patients with early suggestive ALS; finished two open-name specialist dazed Stage 2 clinical preliminaries on the mind’s energy metabolites; finished Stage 2 clinical preliminary for the therapy of visual pathway shortfalls in constant optic neuropathy for remyelination in stable backsliding Various Sclerosis; and a second Stage 2 clinical preliminary for the treatment of patients with Parkinson’s Illnesses. The organization’s items likewise incorporate CNM-AgZn17, a gel polymer suspension of silver and zinc particles that is being produced for the treatment of irresistible sicknesses and to help wound recuperating; and CNM-ZnAg, an expansive range antiviral and antibacterial specialist to treat contamination illness, like Coronavirus and to offer resistant help for side effect goal. It likewise advertises and circulates dietary enhancements containing rMetx, a watery zinc-silver particle dietary enhancement; and KHC46, a fluid gold dietary enhancement of extremely low-focus Au nanoparticles. The organization is settled in Salt Lake City, Utah.

2.Gamida Cell

Stock Price: $0.41 (+$0.01)
PE Ratio: -1.38
Market Cap: $43.58 million
Average Trading Volume: 2.51 million shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $5.40 (1,208.5% Upside)

Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company’s lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with hematologic malignancies, as well as in Phase II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, an investigational NK cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was incorporated in 1998 and is headquartered in Jerusalem, Israel.

3.Jasper

Stock Price: $0.79 (+$0.07)

PE Ratio: -0.95

Market Cap: $88.03 Million

Average Trading Volume: 1.36 million Share

Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)

Consensus Price Target: $5.96 (655.7% Upside)

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and novel conditioning regimens for stem cell transplantation and ex-vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company’s lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is headquartered in Redwood City, California.

4.Unicycive Therapeutics

Stock Price: $0.87 (-$0.01)

PE Ratio: -0.50

Market Cap: $30.16 Million

Average Trading Volume: 230,055 Share

Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)

Consensus Price Target: $8.88 (922.8% Upside)

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

5.Affimed

Stock Price: $0.63 (+$0.09)
PE Ratio: -0.74
Market Cap: $93.34 million
Average Trading Volume: 956,302 shares
Consensus Rating: Moderate Buy (5 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $5.33 (753.3% Upside)

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia. The company also develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. In addition, it has collaboration with Artiva Biotherapeutics to develop the combination of AFM13 with Artiva’s AB-101 NK cell therapy; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and research collaboration and license agreement with Genentech for the development and commercialization of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.

These are the best penny stocks to buy now. for another stock related information you can check our another articles.

Frequently Asked Questions: About best penny stocks to buy now

What are Penny Stocks?

Penny stocks typically refer to stocks with a low share price, often trading for less than $5 per share. These stocks usually belong to smaller companies with lower market capitalization.

Why are Penny Stocks Risky?

Penny stocks are considered risky due to their volatility, lower liquidity, and the potential for price manipulation. Smaller companies may also have a higher likelihood of financial instability.

How Can I Find Penny Stocks to Buy?

Investors often use stock screeners, financial news, and forums to identify potential penny stock opportunities. However, it’s crucial to verify information and not rely solely on promotional material.